New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
Recruiting
- Conditions
- Ovarian Cancer
- Registration Number
- NCT05410028
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.
- Detailed Description
Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically confirmed patients relapse. At least 50 patients are expected to be enrolled.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 1000
Inclusion Criteria
- Female
- A diagnosed patient with epithelial ovarian cancer
- Age ≤ 70
Exclusion Criteria
- Male
- Suffering from other malignant tumors
- Non-compliant patient
- Age above 70
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune Inflammation-Related Protein Complexes 2 years The change of immune inflammation-related protein complexes
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China